Sfoglia per Autore
Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase.
2011 Breccia, M; Girmenia, C; Latagliata, R; Loglisci, G; Santopietro, M; Federico, V; Petrucci, L; Serrao, A; Salaroli, A; Alimena, Giuliana
Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib.
2011 Breccia, M; Santopietro, M; Cannella, L; Federico, V; Loglisci, G; Serrao, A; Petrucci, L; Salaroli, A; Nanni, M; Propris, Ms; Diverio, D; Alimena, Giuliana
Combination of azacitidine and ESA in myelodysplastic patients: The need for prospective studies
2012 Massimo, Breccia; Giuseppina, Loglisci; Adriano, Salaroli; Alessandra, Serrao; Luigi, Petrucci; Irene, Zacheo; Alimena, Giuliana
5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials.
2012 Breccia, M; Loglisci, G; Salaroli, A; Serrao, A; Petrucci, L; Mancini, M; Alimena, Giuliana
Prognostic Features of Myelodysplastic Syndrome Patients Aged < 50 years: Update of a Single Institution Experience.
2012 Breccia, M; Finsinger, P; Loglisci, G; Santopietro, M; Salaroli, A; Serrao, A; Latagliata, R; Volpicelli, P; Petrucci, L; Nanni, M; Alimena, Giuliana
Neutropenia at baseline could indicate poor prognosis in low/intermediate risk myelodysplastic syndrome patients
2012 Breccia, Massimo; Giuseppina, Loglisci; Adriano, Salaroli; Paola, Finsinger; Serrao, Alessandra; Petrucci, Luigi; Alimena, Giuliana
Evaluation of prognostic factors for overall survival in patients with chronic myelomonocytic leukemia by different scoring systems: which is the best?
2012 Breccia, M; Finsinger, P; Loglisci, G; Colafigli, G; Serrao, A; Salaroli, A; Petrucci, L; Alimena, Giuliana
Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.
2012 Breccia, M; Finsinger, P; Loglisci, G; Federico, V; Santopietro, M; Colafigli, G; Petrucci, L; Salaroli, A; Serrao, A; Latagliata, R; Alimena, Giuliana
LONG-TERM FOLLOW-UP OF PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN COMPLETE MOLECULAR RESPONSE WITH ALPHA-INTERFERON AFTER TREATMENT DISCONTINUATION
2014 Latagliata, R; Romano, A; Mancini, M; Breccia, M; Carmosino, I; Vozella, F; Montagna, C; Volpicelli, P; Petrucci, L; Serao, A; Molica, M; Salaroli, A; Diverio, D; Tafuri, Agostino; Alimena, Giuliana
Management of elderly and unfit patients with chronic lymphocytic leukemia
2016 Mauro, Francesca Romana; Salaroli, Adriano; Caputo, Maria Denise; Colafigli, Gioia; Petrucci, Luigi; Campanelli, Melissa; Ferretti, Antonietta; Guarini, Anna; Foa, Roberto
Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response
2016 Latagliata, R.; Romano, A.; Mancini, M.; Breccia, Massimo; Carmosino, I.; Vozella, F.; Montagna, C.; Volpicelli, P.; De Angelis, F.; Petrucci, L.; Serrao, A.; Molica, M.; Salaroli, A.; Diverio, D.; Alimena, G.
A prospective unicentric survey on donor-specific antibodies DSA and desensitization strategy
2016 Iori, A. P.; La Rocca, U.; Perrone, M. P.; Cinti, P.; Barberi, W.; Torelli, G. F.; Shafii Bafti, M.; Gozzer, M.; Petrucci, Luigi; Laurenti, Luca; Lombardi, Laura; Lucani, B.; Foà, R.; Girelli, G.
PREDICTIVE FACTORS FOR INFECTIOUS ADVERSE EVENTS IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA TREATED WITH BENDAMUSTINE-RITUXIMAB (R)+/- R MAINTENANCE. RESULTS OF A RETROSPECTIVE ANALYSIS
2017 DI ROCCO, Alice; DE ANGELIS, Federico; Petrucci, L; Vozzella, F; De Benedittis, D; Foa, Roberto; Martelli, Maurizio
EFFICACY, SAFETY AND COST ANALYSIS OF SUBCUTANEOUS VS INTRAVENOUS RITUXIMAB IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH RCHOP
2017 DI ROCCO, Alice; Scerbo, Gaia; Ansuinelli, Michela; Petrucci, Luigi; LA ROCCA, Ursula; Coggi, Angela; Arduini, Enrica; Foa, Roberto; Martelli, Maurizio
Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia
2017 Mauro, Francesca Romana; Morabito, Fortunato; Vincelli, Iolanda D.; Petrucci, Luigi; Campanelli, Melissa; Salaroli, Adriano; Uccello, Giuseppina; Petrungaro, Annamaria; Ronco, Francesca; Raponi, Sara; Nanni, Mauro; Neri, Antonino; Ferrarini, Manlio; Guarini, Anna; Foa, Roberto; Gentile, Massimo
Lymphomatoid granulomatosis and large granular lymphocyte leukemia, a rare association of two lymphoproliferative disorders
2018 De Luca, Giulia; Trasarti, Stefania; Bizzoni, Luisa; del Giudice, Ilaria; Della Starza, Irene; De Propris, Maria Stefania; Gentile, Giuseppe; Mancini, Francesca; Mantovani, Sara; Petrucci, Luigi; Tabanelli, Valentina; Guarini, Anna; Vignetti, Marco; Foà, Robin
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Patients: A Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy
2019 Di Rocco, Alice; Di Rocco, Arianna; Farcomeni, Alessio; Petrucci, Luigi; De Luca, Giulia; Mazzon, Federico; Martelli, Maurizio; Foà, Robin
The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma. a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI)
2019 Annibali, O.; Hohaus, S.; Marchesi, F.; Cantonetti, M.; Di Rocco, A.; Tomarchio, V.; Di Napoli, A.; Pelliccia, S.; Battistini, R.; Anticoli Borza, P.; Abruzzese, E.; Cenfra, N.; Andriani, A.; Tesei, C.; Alma, E.; Palombi, F.; Pupo, L.; Petrucci, L.; Becilli, M.; Maiolo, E.; Bellesi, S.; Cuccaro, A.; D'Alo, F.; Cox, M. C.
COVID-19 in patients with hematologic disorders undergoing therapy: perspective of a large referral hematology center in Rome
2020 Girmenia, C.; Gentile, G.; Micozzi, A.; Petrucci, L.; Malaspina, F.; Di Prima, A.; Baldacci, E.; Bianchi, S.; Pugliese, P.; Turriziani, O.; Antonelli, G.; Tombolini, V.; Foa, R.; Martelli, M.
Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy
2020 Di Rocco, A.; Cuneo, A.; Di Rocco, A.; Merli, F.; De Luca, G.; Petrucci, L.; Ansuinelli, M.; Penna, D.; Rotondo, F.; Rigolin, G. M.; Giamo, M.; Re, F.; Farcomeni, A.; Martelli, M.; Foa, R.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase. | 2011 | Breccia, M; Girmenia, C; Latagliata, R; Loglisci, G; Santopietro, M; Federico, V; Petrucci, L; Serrao, A; Salaroli, A; Alimena, Giuliana | |
| Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib. | 2011 | Breccia, M; Santopietro, M; Cannella, L; Federico, V; Loglisci, G; Serrao, A; Petrucci, L; Salaroli, A; Nanni, M; Propris, Ms; Diverio, D; Alimena, Giuliana | |
| Combination of azacitidine and ESA in myelodysplastic patients: The need for prospective studies | 2012 | Massimo, Breccia; Giuseppina, Loglisci; Adriano, Salaroli; Alessandra, Serrao; Luigi, Petrucci; Irene, Zacheo; Alimena, Giuliana | |
| 5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials. | 2012 | Breccia, M; Loglisci, G; Salaroli, A; Serrao, A; Petrucci, L; Mancini, M; Alimena, Giuliana | |
| Prognostic Features of Myelodysplastic Syndrome Patients Aged < 50 years: Update of a Single Institution Experience. | 2012 | Breccia, M; Finsinger, P; Loglisci, G; Santopietro, M; Salaroli, A; Serrao, A; Latagliata, R; Volpicelli, P; Petrucci, L; Nanni, M; Alimena, Giuliana | |
| Neutropenia at baseline could indicate poor prognosis in low/intermediate risk myelodysplastic syndrome patients | 2012 | Breccia, Massimo; Giuseppina, Loglisci; Adriano, Salaroli; Paola, Finsinger; Serrao, Alessandra; Petrucci, Luigi; Alimena, Giuliana | |
| Evaluation of prognostic factors for overall survival in patients with chronic myelomonocytic leukemia by different scoring systems: which is the best? | 2012 | Breccia, M; Finsinger, P; Loglisci, G; Colafigli, G; Serrao, A; Salaroli, A; Petrucci, L; Alimena, Giuliana | |
| Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population. | 2012 | Breccia, M; Finsinger, P; Loglisci, G; Federico, V; Santopietro, M; Colafigli, G; Petrucci, L; Salaroli, A; Serrao, A; Latagliata, R; Alimena, Giuliana | |
| LONG-TERM FOLLOW-UP OF PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN COMPLETE MOLECULAR RESPONSE WITH ALPHA-INTERFERON AFTER TREATMENT DISCONTINUATION | 2014 | Latagliata, R; Romano, A; Mancini, M; Breccia, M; Carmosino, I; Vozella, F; Montagna, C; Volpicelli, P; Petrucci, L; Serao, A; Molica, M; Salaroli, A; Diverio, D; Tafuri, Agostino; Alimena, Giuliana | |
| Management of elderly and unfit patients with chronic lymphocytic leukemia | 2016 | Mauro, Francesca Romana; Salaroli, Adriano; Caputo, Maria Denise; Colafigli, Gioia; Petrucci, Luigi; Campanelli, Melissa; Ferretti, Antonietta; Guarini, Anna; Foa, Roberto | |
| Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response | 2016 | Latagliata, R.; Romano, A.; Mancini, M.; Breccia, Massimo; Carmosino, I.; Vozella, F.; Montagna, C.; Volpicelli, P.; De Angelis, F.; Petrucci, L.; Serrao, A.; Molica, M.; Salaroli, A.; Diverio, D.; Alimena, G. | |
| A prospective unicentric survey on donor-specific antibodies DSA and desensitization strategy | 2016 | Iori, A. P.; La Rocca, U.; Perrone, M. P.; Cinti, P.; Barberi, W.; Torelli, G. F.; Shafii Bafti, M.; Gozzer, M.; Petrucci, Luigi; Laurenti, Luca; Lombardi, Laura; Lucani, B.; Foà, R.; Girelli, G. | |
| PREDICTIVE FACTORS FOR INFECTIOUS ADVERSE EVENTS IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA TREATED WITH BENDAMUSTINE-RITUXIMAB (R)+/- R MAINTENANCE. RESULTS OF A RETROSPECTIVE ANALYSIS | 2017 | DI ROCCO, Alice; DE ANGELIS, Federico; Petrucci, L; Vozzella, F; De Benedittis, D; Foa, Roberto; Martelli, Maurizio | |
| EFFICACY, SAFETY AND COST ANALYSIS OF SUBCUTANEOUS VS INTRAVENOUS RITUXIMAB IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH RCHOP | 2017 | DI ROCCO, Alice; Scerbo, Gaia; Ansuinelli, Michela; Petrucci, Luigi; LA ROCCA, Ursula; Coggi, Angela; Arduini, Enrica; Foa, Roberto; Martelli, Maurizio | |
| Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia | 2017 | Mauro, Francesca Romana; Morabito, Fortunato; Vincelli, Iolanda D.; Petrucci, Luigi; Campanelli, Melissa; Salaroli, Adriano; Uccello, Giuseppina; Petrungaro, Annamaria; Ronco, Francesca; Raponi, Sara; Nanni, Mauro; Neri, Antonino; Ferrarini, Manlio; Guarini, Anna; Foa, Roberto; Gentile, Massimo | |
| Lymphomatoid granulomatosis and large granular lymphocyte leukemia, a rare association of two lymphoproliferative disorders | 2018 | De Luca, Giulia; Trasarti, Stefania; Bizzoni, Luisa; del Giudice, Ilaria; Della Starza, Irene; De Propris, Maria Stefania; Gentile, Giuseppe; Mancini, Francesca; Mantovani, Sara; Petrucci, Luigi; Tabanelli, Valentina; Guarini, Anna; Vignetti, Marco; Foà, Robin | |
| Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Patients: A Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy | 2019 | Di Rocco, Alice; Di Rocco, Arianna; Farcomeni, Alessio; Petrucci, Luigi; De Luca, Giulia; Mazzon, Federico; Martelli, Maurizio; Foà, Robin | |
| The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma. a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI) | 2019 | Annibali, O.; Hohaus, S.; Marchesi, F.; Cantonetti, M.; Di Rocco, A.; Tomarchio, V.; Di Napoli, A.; Pelliccia, S.; Battistini, R.; Anticoli Borza, P.; Abruzzese, E.; Cenfra, N.; Andriani, A.; Tesei, C.; Alma, E.; Palombi, F.; Pupo, L.; Petrucci, L.; Becilli, M.; Maiolo, E.; Bellesi, S.; Cuccaro, A.; D'Alo, F.; Cox, M. C. | |
| COVID-19 in patients with hematologic disorders undergoing therapy: perspective of a large referral hematology center in Rome | 2020 | Girmenia, C.; Gentile, G.; Micozzi, A.; Petrucci, L.; Malaspina, F.; Di Prima, A.; Baldacci, E.; Bianchi, S.; Pugliese, P.; Turriziani, O.; Antonelli, G.; Tombolini, V.; Foa, R.; Martelli, M. | |
| Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy | 2020 | Di Rocco, A.; Cuneo, A.; Di Rocco, A.; Merli, F.; De Luca, G.; Petrucci, L.; Ansuinelli, M.; Penna, D.; Rotondo, F.; Rigolin, G. M.; Giamo, M.; Re, F.; Farcomeni, A.; Martelli, M.; Foa, R. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile